Cobas 8000 e801 unit

Since the epidemic caused by the Omicron variant in Taiwan began in May 2022, we retrieved data from 365 KTRs who had received at least their 1st dose of various COVID vaccines until June 30, 2022. In KTRs (n = 168) who had received at least the 2nd vaccination, we assessed the relationship between kidney function and SCOV-2 antibody response. Outcomes were analyzed according to various vaccination statuses until September 30, 2022, which was the time before the border was opened for tourism. The study was approved by the Institutional Review Board of Taichung Veterans General Hospital (CE21377A). Antibody tests for SCOV-2 were performed using the quantitative Elecsys Anti-SARS-CoV-2 S assay (Anti-S; Roche Diagnostics, Mannheim, Germany) with a Cobas 8000 e801 unit (Roche Diagnostics) according to the manufacturer's protocol, with a range of 0.4 to 250 U/mL. The value ≥0.8 U/mL was considered positive if values above the measuring range were diluted 10-fold. The statistical significance was set at P ≤ 0.05. Statistical analyses were conducted using IBM SPSS Statistics for Windows, Version 24.0 (IBM SPSS, Inc, Armonk, NY, United States).

The samples were collected 4 weeks after D1 and 4 weeks after D2 in lung transplant recipients and healthy controls. Antibody tests for SARS-CoV-2 were performed using the quantitative Elecsys Anti-SARS-CoV-2 S assay (Elecsys Anti-S; Roche Diagnostics, Mannheim, Germany) with a Cobas 8000 e801 unit (Roche Diagnostics). The Elecsys anti-S assay uses a recombinant protein representing the receptor binding domain of the S antigen, which favors the quantitative determination of high-affinity antibodies against SARS-CoV-2. The results are reported as the concentration of antibodies with a measurement range of 0.4 to 250 U/mL; samples with values above the measuring range were diluted 10-fold. The values <0.8 U/mL were interpreted as nonreactive (negative) and ≥0.8 U/mL as reactive (positive).